Hey team..... I took the jab all in good, clean fun! Besides my recent spelling lesson (quite vs quiet)... I now have to take my time to re-read my posts....

What I meant to say was that with all the exclusivity blocks (implying no competition), the early treatment mind set of the ADA, the willingness of the insurance industry just waiting to work with the ADA to create updated codes to address early treatment (ask Craig Gimbel), the document and early detect capability of OCT, the acceptance of OCT in other markets, low-to-zero risk obtaining FDA approval because OCT is in volume production, the Lantis team (we often speak highly of Stan.... but another key figure is Greg Gimbel D.D.S who is well known in the dentistry world...take a moment to read his profile at the LLSR web site..... it is his relationship with key peers in the industry that led LLSR to acquiring the rights to NIR from his buddy Daniel Fried who wrote a number of papers on NIR.... a good old boy network taking care of each other....) and..... I could continue but you get the point..... is that "LLSR will be a major player" for us in the stock market.

I've done a number of conservative evaluations assuming a 10% penetration model (and comparing to Meditec already achieving 10% penetration) all with middle-of-the-road to conservative parameters..... the lowest is $3 and the highest is $5.25..... I once took a leap of faith at a few aggressive parameters and got to $8.75.... but I had been drinking and needed to go back to rehab.... because I got all crazy thinking about this number times my shares.....snicker... snicker...

I would be interested in other team member's speculation about LLSR's future price assuming a selling price of $25K, 200K worldwide offices and a 10% penetration rate assumed within 3 years of product launch......

My models at the time did not include the impact of NIR.... I feel safe to suggest a $4-to-$5 stock price (assuming no more shares are created) and an accelerated penetration rate once both NIR/OCT are integrated on the same platform and the software updated to detect soft tissue issues..... the only thing I'm worried about is that Stan may sell the company at a price of $2 because he has a history of starting up companies and selling them (not to mention his massive amount of shares).... I have no inside information here.... except....I asked Stan this very question about 1.5 years ago.... he acknowledged he had a history of selling his upstart companies but said OCT has so much potential for his company that he would be a fool to sell early and that he was sitting on the mother of all gold mines.

Finally.... to address the funding question.... I have concerns about LLSR's ability to raise funds (or any upstart company's ability) in the current climate.... but it is only a timing issue..... all the fundamentals are extremely strong. When I first read Stan's comments recently.... something like...."Now that we have received SEC approval, we are now ready to pursue the next round of funding".... something like that... don't get too specific on my quote if it is a bit out of text.....I was sadly concerned. I am certain LLSR had been trying to get additional funding since last Summer so it seemed like a BS line and I thought I had witnessed my first kink in the LLSR armor. I did address this quote and realized that what Stan was suggesting is that there are a few funding paths that have been "on-hold" waiting for LLSR to achieve SEC approval and move up to at least the OTCBB.... an act of credibility.... so I believe Stan is now working these funding channels and hope he obtains at least $2M during the 2nd Qtr.

Until my next post, I remain

Enlightened

ps: I miss "shaffer" and hope he is doing well on the ShamWow Board... hope he checks in from time-to-time. He is really a great guy but going thru some tough times given he got sucked into a bad investment with the broker who also represented LLSR during the first two private placements. We always need posting members who have alternate view points.